Rare lephants
Screener

CARING BRANDS, INC.

CABR ·Consumer Defensive, Household & Personal Products, United States
Analysis › Company Overview

Caring Brands, Inc. (CABR)

Overview

Caring Brands, Inc. is a micro-cap wellness consumer products company headquartered in the United States, developing over-the-counter (OTC) and cosmetic dermatology products for conditions such as psoriasis, vitiligo, hair loss, and eczema. The company was founded in 2020, operated as a subsidiary of Safety Shot, Inc. until being spun off as an independent entity in 2024, and completed its Nasdaq listing (ticker CABR) in November 2025. It is an early-stage, pre-scale company with a market capitalization of roughly $14 million, nominal revenue, and only three full-time employees, and its FY2025 10-K explicitly discloses "substantial doubt" about its ability to continue as a going concern.

What They Do & How They Make Money

Caring Brands develops, licenses, and sells a small portfolio of dermatology and wellness products, generating revenue through a mix of direct e-commerce sales and international licensing/royalty agreements rather than a large owned commercial infrastructure. Its lead near-term product, Hair Enzyme Booster (JW-700), is designed to increase sulfotransferase enzyme activity and enhance the efficacy of minoxidil in hair-loss treatment; it launched on Amazon in October 2024 and has been licensed to Taisho Pharmaceutical, Japan's leading minoxidil seller, under a deal providing up to $200,000 in milestone payments plus a 3% royalty. Its other flagship product, Photocil, is a narrow-band UV filter for psoriasis and vitiligo that has been sold in India since 2022 (with a planned 2026 U.S. relaunch after an earlier unsuccessful 2022–2023 U.S. attempt) and is licensed to Cosmofix/San Pellegrino for distribution across India and 31 other territories, also for a 3% royalty. Two additional products — CB-101, a topical eczema treatment, and NoStingz, a UV and jellyfish-sting sunscreen — remain in reformulation with no material revenue to date. Manufacturing is outsourced to third parties (Stella Industries in India and DCR Labs in Florida), keeping the company's fixed cost base low but making it dependent on contract manufacturers for FDA CGMP-compliant production. The company reported a net loss of $6.28 million in FY2025 (versus $1.52 million in FY2024) on essentially nominal product revenue, reflecting a business still in commercial launch rather than scaled operating mode.

Competitors

Caring Brands competes against far larger, better-capitalized companies across each of its target indications rather than a single peer group:

  • Psoriasis/vitiligo: Large biologics and specialty pharma makers, including IL-23 inhibitor products (roughly 31% market share) and IL-17 inhibitor products (roughly 23% share), and Incyte's ruxolitinib (Opzelura), the leading FDA-approved vitiligo treatment.
  • Hair loss: Established OTC minoxidil brands (e.g., Church & Dwight's Rogaine and store-brand equivalents) in a minoxidil market valued at roughly $1.5 billion in 2022 and projected to reach $2.5 billion by 2032.
  • Eczema: Established prescription and OTC eczema treatments from major dermatology and consumer-health companies.

Competitive Position

Caring Brands' position rests on a small number of issued and pending patents (including U.S. patents on Hair Enzyme Booster, expiring 2039, and on Photocil, expiring 2032) and early clinical/commercial validation from a name-brand Japanese licensing partner (Taisho). These provide some intellectual-property protection and third-party credibility, but the company has essentially no brand recognition with consumers, minimal revenue, and a workforce of only three employees, leaving it with no meaningful economies of scale, marketing reach, or distribution advantage versus incumbent dermatology and OTC players. Its going-concern disclosure underscores the central risk: continued operations depend on raising additional external financing, and any funding shortfall could force the company to scale back or discontinue operations. Execution risk is also significant — CB-101 and NoStingz remain unlaunched, Photocil's prior U.S. attempt was unsuccessful, and success now depends on licensing partners (Taisho, Cosmofix/San Pellegrino) executing commercial launches largely outside the company's direct control. Caring Brands' path forward depends on converting its licensing pipeline into recurring royalty revenue before its cash position and going-concern pressure force a more difficult outcome.

Sources